Amgen's TEZSPIRE Shows Positive Phase 3 Trial Results for Eosinophilic Esophagitis

Amgen announced that its drug TEZSPIRE achieved positive outcomes in a Phase 3 clinical trial for eosinophilic esophagitis. The trial met both co-primary and all key secondary endpoints, indicating a significant step forward in developing a treatment for this condition. This advancement could offer a new therapeutic option for patients.